Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan C Short

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Clinical and Translational Radiation Oncology|March 30, 2018
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT statusBen Fulton, Susan C Short, Allan James, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2017
Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging-Only Radiation TherapyEmily Johnstone, Jonathan J Wyatt, Ann M Henry, et al.
BMC Cancer|January 15, 2024
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trialDivyalakshmi Bhaskaran, Joshua Savage, Amit Patel, et al.
Frontiers in Oncology|April 2, 2019
FGFR1 Expression and Role in Migration in Low and High Grade Pediatric GliomasNaomi Egbivwie, Julia V Cockle, Matthew Humphries, et al.
Molecular Oncology|December 16, 2014
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signatureJosie Hayes, Helene Thygesen, Charlotte Tumilson, et al.
Stem Cell Reports|January 12, 2017
RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem CellsHarry O King, Tim Brend, Helen L Payne, et al.
Neuro-Oncology Advances|July 1, 2024
In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastomaJemma Castle, Gary Shaw, Dominic Weller, et al.
Biomedicines|January 21, 2022
Drug Resistance in Glioma Cells Induced by a Mesenchymal-Amoeboid Migratory SwitchSophie E Ketchen, Filomena O Gamboa-Esteves, Sean E Lawler, et al.
Neuro-Oncology Practice|January 15, 2024
Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiativeEmilie Le Rhun, Florien Boele, Giuseppe Minniti, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2024
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM TrialSarah Derby, Mark R Jackson, Karin Williams, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Clinical and Translational Radiation Oncology|March 30, 2018
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT statusBen Fulton, Susan C Short, Allan James, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2017
Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging-Only Radiation TherapyEmily Johnstone, Jonathan J Wyatt, Ann M Henry, et al.
BMC Cancer|January 15, 2024
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trialDivyalakshmi Bhaskaran, Joshua Savage, Amit Patel, et al.
Frontiers in Oncology|April 2, 2019
FGFR1 Expression and Role in Migration in Low and High Grade Pediatric GliomasNaomi Egbivwie, Julia V Cockle, Matthew Humphries, et al.
Molecular Oncology|December 16, 2014
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signatureJosie Hayes, Helene Thygesen, Charlotte Tumilson, et al.
Stem Cell Reports|January 12, 2017
RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem CellsHarry O King, Tim Brend, Helen L Payne, et al.
Neuro-Oncology Advances|July 1, 2024
In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastomaJemma Castle, Gary Shaw, Dominic Weller, et al.
Biomedicines|January 21, 2022
Drug Resistance in Glioma Cells Induced by a Mesenchymal-Amoeboid Migratory SwitchSophie E Ketchen, Filomena O Gamboa-Esteves, Sean E Lawler, et al.
Neuro-Oncology Practice|January 15, 2024
Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiativeEmilie Le Rhun, Florien Boele, Giuseppe Minniti, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2024
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM TrialSarah Derby, Mark R Jackson, Karin Williams, et al.
Pageof 8